Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease

INTRODUCTION: Roflumilast is a phosphodiesterase-4 inhibitor, which can decrease exacerbation in patients with chronic obstructive pulmonary disease (COPD). However, adverse effects are a major barrier to medication use, and little is known regarding the risk factors for discontinuation of roflumila...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kyung Hoon, Kang, Hye Seon, Kim, Ju Sang, Yoon, Hyoung Kyu, Kim, Sung Kyoung, Rhee, Chin Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720347/
https://www.ncbi.nlm.nih.gov/pubmed/29270006
http://dx.doi.org/10.2147/COPD.S143967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720347/
https://www.ncbi.nlm.nih.gov/pubmed/29270006
http://dx.doi.org/10.2147/COPD.S143967

Ejemplares similares